Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.

Hamada S, Ichiyasu H, Ikeda T, Inaba M, Kashiwabara K, Sadamatsu T, Sato N, Akaike K, Okabayashi H, Saruwatari K, Tomita Y, Saeki S, Hirata N, Yoshinaga T, Fujii K.

BMC Pulm Med. 2019 Apr 2;19(1):72. doi: 10.1186/s12890-019-0838-2.

2.

Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.

Saruwatari K, Ikeda T, Saeki S, Shingu N, Imamura K, Komatu T, Ushijima S, Maruyama H, Kashiwabara K, Tomita Y, Ichiyasu H, Fujii K, Sakagami T.

Anticancer Res. 2019 Feb;39(2):923-931. doi: 10.21873/anticanres.13195.

PMID:
30711977
3.

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.

Saruwatari K, Sato R, Nakane S, Sakata S, Takamatsu K, Jodai T, Mito R, Horio Y, Saeki S, Tomita Y, Sakagami T.

Cancers (Basel). 2019 Jan 24;11(2). pii: E140. doi: 10.3390/cancers11020140.

4.

A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.

Jodai T, Yoshida C, Sato R, Kakiuchi Y, Sato N, Iyama S, Kimura T, Saruwatari K, Saeki S, Ichiyasu H, Fujii K, Tomita Y.

Immun Inflamm Dis. 2019 Mar;7(1):3-6. doi: 10.1002/iid3.238. Epub 2018 Nov 21.

5.

Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients.

Akaike K, Saruwatari K, Okabayashi H, Hamada S, Jodai Y, Jodai T, Sakata S, Iyama S, Sato R, Iriki T, Tomita Y, Saeki S, Ichiyasu H, Fujii K.

Anticancer Res. 2018 Nov;38(11):6543-6550. doi: 10.21873/anticanres.13020.

PMID:
30396984
6.

Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient.

Horio Y, Takamatsu K, Tamanoi D, Sato R, Saruwatari K, Ikeda T, Nakane S, Nakajima M, Saeki S, Ichiyasu H, Fujii K, Tomita Y.

Eur J Immunol. 2018 Oct;48(10):1764-1767. doi: 10.1002/eji.201847645. Epub 2018 Jul 19.

PMID:
29981156
7.

Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.

Ichikawa T, Saruwatari K, Mimaki S, Sugano M, Aokage K, Kojima M, Hishida T, Fujii S, Yoshida J, Kuwata T, Ochiai A, Suzuki K, Tsuboi M, Goto K, Tsuchihara K, Ishii G.

Lung Cancer. 2017 Nov;113:134-139. doi: 10.1016/j.lungcan.2017.10.001. Epub 2017 Oct 5.

PMID:
29110840
8.

Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy.

Saruwatari K, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ohe Y, Goto K.

Clin Lung Cancer. 2016 Nov;17(6):581-587. doi: 10.1016/j.cllc.2016.05.022. Epub 2016 Jun 16.

PMID:
27424806
9.

The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer.

Goto M, Naito M, Saruwatari K, Hisakane K, Kojima M, Fujii S, Kuwata T, Ochiai A, Nomura S, Aokage K, Hishida T, Yoshida J, Yokoi K, Tsuboi M, Ishii G.

J Cancer Res Clin Oncol. 2017 Feb;143(2):215-223. doi: 10.1007/s00432-016-2271-8. Epub 2016 Sep 17.

PMID:
27640003
10.

Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.

Saruwatari K, Ikemura S, Sekihara K, Kuwata T, Fujii S, Umemura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ochiai A, Kohrogi H, Tsuboi M, Goto K, Ishii G.

Lung Cancer. 2016 Jan;91:7-14. doi: 10.1016/j.lungcan.2015.11.012. Epub 2015 Nov 15.

PMID:
26711928
11.

The association of intravascular stromal cells with prognosis in high-grade neuroendocrine carcinoma of the lung.

Sekihara K, Hishida T, Ikemura S, Saruwatari K, Morise M, Kuwata T, Fujii S, Kojima M, Ochiai A, Funai K, Aokage K, Yoshida J, Tsuboi M, Ishii G.

J Cancer Res Clin Oncol. 2016 May;142(5):905-12. doi: 10.1007/s00432-015-2098-8. Epub 2015 Dec 22.

PMID:
26696594
12.

Unique intravascular tumor microenvironment predicting recurrence of lung squamous cell carcinoma.

Hisakane K, Saruwatari K, Fujii S, Kirita K, Umemura S, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Kuwata T, Ochiai A, Gemma A, Tsuboi M, Goto K, Ishii G.

J Cancer Res Clin Oncol. 2016 Mar;142(3):593-600. doi: 10.1007/s00432-015-2068-1. Epub 2015 Oct 31.

PMID:
26521256
13.

Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.

Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G, Matsumoto S, Sugiyama E, Ochiai A, Abe R, Goto K, Esumi H, Tsuchihara K.

J Biol Chem. 2015 Jul 10;290(28):17495-504. doi: 10.1074/jbc.M115.660498. Epub 2015 May 28.

14.

Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.

Sakata S, Sasaki J, Saeki S, Hamada A, Kishi H, Nakamura K, Tanaka H, Notsute D, Sato R, Saruwatari K, Iriki T, Akaike K, Fujii S, Hirosako S, Kohrogi H.

Oncology. 2015;88(4):201-7. doi: 10.1159/000369255. Epub 2014 Dec 6.

PMID:
25502447
15.

[Maintenance therapy for advanced non-small-cell lung cancer].

Saruwatari K, Yoh K.

Gan To Kagaku Ryoho. 2014 Aug;41(8):926-31. Review. Japanese.

PMID:
25132023

Supplemental Content

Loading ...
Support Center